

Resource Summary Report

Generated by ASWG on Aug 2, 2026

Indiana University School of Medicine Biospecimen Collection and Banking Core Facility

RRID:SCR_025529

Type: Tool

Proper Citation

Indiana University School of Medicine Biospecimen Collection and Banking Core Facility
(RRID:SCR_025529)

Resource Information

URL: <https://cancer.iu.edu/research/shared-facilities/bc2.html>

Proper Citation: Indiana University School of Medicine Biospecimen Collection and Banking Core Facility (RRID:SCR_025529)

Description: Core offers services related to biospecimen and data collection in support of cancer research. Provides collection of well-annotated samples from patients with malignancy and normal controls to support studies exploring the biologic basis of cancer, move basic findings to clinic, and probe the biology underlying clinical and population phenomena.

Synonyms: , Biospecimen Collection and Banking Core (BC2), Indiana University School of Medicine Biospecimen Collection and Banking Core

Resource Type: core facility, service resource, access service resource

Keywords: ABRF, biospecimen collection, data collection, cancer research,

Resource Name: Indiana University School of Medicine Biospecimen Collection and Banking Core Facility

Resource ID: SCR_025529

Alternate IDs: ABRF_2850

Alternate URLs: <https://indianactsi.org/servicecores/core/44/>,
<https://coremarketplace.org/?FacilityID=2850&citation=1>

Record Creation Time: 20240726T053304+0000

Record Last Update: 20260801T191319+0000

Ratings and Alerts

No rating or validation information has been found for Indiana University School of Medicine Biospecimen Collection and Banking Core Facility.

No alerts have been found for Indiana University School of Medicine Biospecimen Collection and Banking Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Sheth AS, et al. (2025) PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. Cancer research communications, 5(4), 648.